Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand

Cardiology Journal

Volumn 19, Issue 1, 2012, Pages 20-28

  Stach, Ksenija ^a   Nguyen, Xuan Duc ^a   Lang, Siegfried ^a   Elmas, Elif ^a   Weiß, Christel ^a   Borggrefe, Martin ^a   Fischer, Joachim ^a   Kälsch, Thorsten ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atherosclerosis; Atorvastatin; Endothelial cells; Platelets; Simvastatin

Indexed keywords

ATORVASTATIN; CD40 LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE 14; PADGEM PROTEIN; SIMVASTATIN; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CELL CONTACT; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; UMBILICAL VEIN;

EID: 84856787520     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: 10.5603/CJ.2012.0005     Document Type: Article

References (51)

1. Jahn J, Dalhoff K, Katus HA. Coronary artery disease: An inflammatory or infectious process. Basic Res Cardiol, 2000; 95 (suppl. 1): I59-I64.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-1143.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342: 836-843.
4. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol, 2005; 100: 93-101.
5. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation, 2001; 103: 1194-1197.
6. Ruggeri ZM. Platelets in atherothrombosis. Nat Med, 2002; 8: 1227-1234.
7. Lusis AJ. Atherosclerosis. Nature, 2000; 407: 233-241.
8. Amirkhosravi A, Alexander M, May K et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost, 1996; 75: 87-95.
9. Gotz AK, Zahler S, Stumpf P, Welsch U, Becker BF. Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction. Basic Res Cardiol, 2005; 100: 413-421.
10. Kälsch T, Elmas E, Nguyen XD et al. Enhanced coagulation activation by in vitro lipopolysaccharide challenge in patients with ventricular fibrillation complicating acute myocardial infarction. J Cardiovasc Electrophysiol, 2005; 16: 858-863.
11. Kälsch T, Nguyen XD, Elmas E et al. Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. Int J Cardiol, 2006; 111: 217-223.
12. Steiner S, Speidl WS, Pleiner J et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation, 2005; 111: 1841-1846.
13. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res, 2004; 61: 498-511.
14. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998; 391: 591-594.
15. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol, 2000; 32: 687-693.
16. Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost, 2004; 30: 441-450.
17. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 1998; 394: 200-203.
18. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa b activation in endothelial cells. J Biol Chem, 2001; 276: 7614-7620.
19. Davies MJ, Gordon JL, Gearing AJ et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol, 1993; 171: 223-229.
20. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol, 2007; 27: 2292-2301.
21. Kitagawa K, Matsumoto M, Sasaki T et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis, 2002; 160: 305-310.
22. Lutgens E, Gorelik L, Daemen MJ et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med, 1999; 5: 1313-1316.
23. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol, 2001; 21: 1104-1117.
24. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994; 94: 2493-2503.
25. Preissner KT, Kanse SM, May AE. Urokinase receptor: A molecular organizer in cellular communication. Curr Opin Cell Biol, 2000; 12: 621-628.
26. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation, 2000; 101: 207-213.
27. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res, 1992; 33: 1569-1582.
28. Bellosta S, Bernini F, Ferri N et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis, 1998; 137 (suppl.): S101-S109.
29. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest, 1998; 101: 2711-2719.
30. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med, 1995; 332: 481-487.
31. Rezaie-Majd A, Prager GW, Bucek RA et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol, 2003; 23: 397-403.
32. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest, 1973; 52: 2745-2756.
33. Gimbrone MA, Jr. Culture of vascular endothelium. Prog Hemost Thromb, 1976; 3: 1-28.
34. Gawaz M, Neumann FJ, Dickfeld T et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation, 1998; 98: 1164-1171.
35. Dickfeld T, Lengyel E, May AE et al. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc Res, 2001; 49: 189-199.
36. May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation, 2002; 106: 2111-2117.
37. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med, 2001; 7: 687-692.
38. Yoshida M, Sawada T, Ishii H et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase--dependent mechanism. Arterioscler Thromb Vasc Biol, 2001; 21: 1165-1171.
39. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long--term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1999; 100: 230-235.
40. Mulhaupt F, Matter CM, Kwak BR et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res, 2003; 59: 755-766.
41. Wagner AH, Gebauer M, Guldenzoph B, Hecker M. 3-hydroxy--3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol, 2002; 22: 1784-1789.
42. Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis, 2006; 188: 51-58.
43. Mosheimer BA, Kaneider NC, Feistritzer C et al. Cd40-ligand--dependent induction of COX-2 gene expression in endothelial cells by activated platelets: Inhibitory effects of atorvastatin. Blood Coagul Fibrinol, 2005; 16: 105-110.
44. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in"active" coronary artery disease. Am J Cardiol, 1990; 65: 168-172.
45. Osman L, Amrani M, Ilsley C, Yacoub MH, Smolenski RT. Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells. Mol Cell Biochem, 2008; 308: 209-217.
46. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol, 1998; 81: 582-587.
47. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLARr* trial). Am J Cardiol, 2003; 92: 152-160.
48. Gentile S, Turco S, Guarino G et al. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab, 2000; 2: 355-362.
49. Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc, 2008; 83: 1316-1325.
50. Lacroix R, Sabatier F, Mialhe A et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: A mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood, 2007; 110: 2432-2439.
51. Patti G, Chello M, Gatto L et al. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Cardiovasc Med (Hagerstown), 2010; 11: 795-800.